425 related articles for article (PubMed ID: 26699492)
1. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
[TBL] [Abstract][Full Text] [Related]
2. ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.
O'Toole JF; Schilling W; Kunze D; Madhavan SM; Konieczkowski M; Gu Y; Luo L; Wu Z; Bruggeman LA; Sedor JR
J Am Soc Nephrol; 2018 Mar; 29(3):869-879. PubMed ID: 29180397
[TBL] [Abstract][Full Text] [Related]
3. Chronic kidney disease: Potassium efflux in APOL1 nephropathy.
Edwards JK
Nat Rev Nephrol; 2016 Mar; 12(3):124. PubMed ID: 26782144
[No Abstract] [Full Text] [Related]
4.
Ma L; Chou JW; Snipes JA; Bharadwaj MS; Craddock AL; Cheng D; Weckerle A; Petrovic S; Hicks PJ; Hemal AK; Hawkins GA; Miller LD; Molina AJ; Langefeld CD; Murea M; Parks JS; Freedman BI
J Am Soc Nephrol; 2017 Apr; 28(4):1093-1105. PubMed ID: 27821631
[No Abstract] [Full Text] [Related]
5. Protein domains of APOL1 and its risk variants.
Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
[TBL] [Abstract][Full Text] [Related]
6. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
7. Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.
Granado D; Müller D; Krausel V; Kruzel-Davila E; Schuberth C; Eschborn M; Wedlich-Söldner R; Skorecki K; Pavenstädt H; Michgehl U; Weide T
J Am Soc Nephrol; 2017 Nov; 28(11):3227-3238. PubMed ID: 28696248
[TBL] [Abstract][Full Text] [Related]
8. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
[TBL] [Abstract][Full Text] [Related]
9. APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?
Olabisi OA; Heneghan JF
Semin Nephrol; 2017 Nov; 37(6):546-551. PubMed ID: 29110762
[TBL] [Abstract][Full Text] [Related]
10. Kidney Disease-Associated
Datta S; Kataria R; Zhang JY; Moore S; Petitpas K; Mohamed A; Zahler N; Pollak MR; Olabisi OA
J Am Soc Nephrol; 2020 Sep; 31(9):2083-2096. PubMed ID: 32675303
[TBL] [Abstract][Full Text] [Related]
11. APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.
Fu Y; Zhu JY; Richman A; Zhang Y; Xie X; Das JR; Li J; Ray PE; Han Z
J Am Soc Nephrol; 2017 Apr; 28(4):1106-1116. PubMed ID: 27864430
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
13. APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans.
Matsha TE; Kengne AP; Masconi KL; Yako YY; Erasmus RT
BMC Genet; 2015 Jun; 16():69. PubMed ID: 26112018
[TBL] [Abstract][Full Text] [Related]
14. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.
Freedman BI; Langefeld CD; Turner J; Núñez M; High KP; Spainhour M; Hicks PJ; Bowden DW; Reeves-Daniel AM; Murea M; Rocco MV; Divers J
Kidney Int; 2012 Oct; 82(7):805-11. PubMed ID: 22695330
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
Sharma AK; Friedman DJ; Pollak MR; Alper SL
FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
[TBL] [Abstract][Full Text] [Related]
16. APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.
Kruzel-Davila E; Shemer R; Ofir A; Bavli-Kertselli I; Darlyuk-Saadon I; Oren-Giladi P; Wasser WG; Magen D; Zaknoun E; Schuldiner M; Salzberg A; Kornitzer D; Marelja Z; Simons M; Skorecki K
J Am Soc Nephrol; 2017 Apr; 28(4):1117-1130. PubMed ID: 27864431
[No Abstract] [Full Text] [Related]
17. APOL1 kidney risk alleles: population genetics and disease associations.
Limou S; Nelson GW; Kopp JB; Winkler CA
Adv Chronic Kidney Dis; 2014 Sep; 21(5):426-33. PubMed ID: 25168832
[TBL] [Abstract][Full Text] [Related]
18. Copy Number Variation at the APOL1 Locus.
Ruchi R; Genovese G; Lee J; Charoonratana VT; Bernhardy AJ; Alper SL; Kopp JB; Thadhani R; Friedman DJ; Pollak MR
PLoS One; 2015; 10(5):e0125410. PubMed ID: 25933006
[TBL] [Abstract][Full Text] [Related]
19. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
20. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]